Alzheimer’s patient finds words again after psilocybin dose

psilocybin in – An 83-year-old woman with severe Alzheimer’s—who had spent years speaking only in monosyllables—began initiating conversations after taking psilocybin from a large oral dose of an Enigma strain of Psilocybe cubensis. Over the following weeks, her urinary contr

For years, the woman at the center of this report could communicate only in monosyllables. After a large oral dose of psilocybin, that changed. Her family and clinicians say she began initiating conversations—one that surfaced after nearly a full day on the drug—and that the improvement carried into the weeks that followed. including regained urinary continence and better mobility.

The patient, who has not been named, is 83 and was diagnosed with Alzheimer’s disease 10 years ago. Her decline in function had been marked for around half that time, alongside urinary incontinence and an inability to get around without assistance.

With the consent of her son, she was given 5 grams of the Enigma strain of Psilocybe cubensis, administered orally. After taking it, she initially began sweating profusely and entered a prolonged deep sleep-like state. Around 19 hours later, her son reported that she was initiating a conversation that included her memories and reflections. That conversation lasted around 4 hours.

In the weeks after the first session. Marcus Lago of the Ankh Cross Association in São Paulo. Brazil—an organisation that focuses on holistic medical practices—watched the change unfold in daily behavior. not just in speech. “Her facial expressions became much more animated; she made prolonged eye contact. smiled responsively and moved with greater agility. ” Lago said. “During a later session she spontaneously said: ‘It feels good to come here.’”.

Lago and colleagues also observed her regaining urinary continence, dressing herself, and spontaneously entering conversations. Off the success of the first trip, about a month later the woman was given another 3 grams of psilocybin. After that second dose, she described surfing with her son on a peaceful island.

“She selected and put on coordinated clothing independently. went to the television room expecting breakfast. recognised contextual details such as a rented car. noticed when someone was unexpectedly absent and repeatedly remained continent for periods in which incontinence had previously been routine. ” Lago said.

Researchers stressed that her Alzheimer’s had not been reversed. Still, they described the case as evidence that psychedelics can acutely alter cognition and brain function—suggesting there may be some residual capacity that the drugs can temporarily tap.

The push to explain what might be happening points to psilocybin’s biology. The report notes that psilocybin activates serotonin receptors in the brain, which is thought to boost plasticity and alter communication between networks.

David Nutt at Imperial College London said he has heard of similar accounts where psychedelics improved brain function in people with neurodegenerative decline. “These accounts don’t prove psychedelics promote longevity and maintain good brain function but are consistent with [their] known anti-inflammatory activity. ” he said.

Understanding Alzheimer’s itself remains part of the backdrop. The report describes the amyloid hypothesis as the leading idea: clumping of a misfolded protein called amyloid-beta between brain cells triggers abnormal formation of a protein called tau inside cells to form tangles. That process is described as leading to neuroinflammation, disruption of neural connections, and cell death. Nutt suggested that some brain dysfunctions may involve one brain circuit suppressing another, and that psychedelics could disrupt such effects.

But the excitement comes with sharp caveats. Albert Garcia-Romeu at Johns Hopkins University in Baltimore. Maryland—who is involved in a study investigating psilocybin’s effects on depression in people with mild cognitive impairment or early Alzheimer’s disease—warned about what this single report can and cannot do. “I have a litany of concerns about the validity of the report and the ethics overall,” Garcia-Romeu said. He pointed out that the paper described the month after the first session but did not specify any longer follow-up duration. or whether improvements persisted. He also noted that the diagnosis was based on symptom assessment rather than more reliable methods such as biomarker testing or neuroimaging.

Because it is a single case report, Garcia-Romeu said it cannot be extrapolated to people with Alzheimer’s as a whole.

Even so, some see enough here to argue for proper clinical research. Rudolph Tanzi at Harvard University said the case is dramatic, while urging restraint. “This is a pretty dramatic case study and while we have to be careful to not make too many conclusions based on one anecdotal event. the findings do suggest a trial may be warranted. ” he said.

psilocybin Alzheimer’s disease Psilocybe cubensis Enigma strain psychedelics serotonin receptors brain plasticity urinary continence neuroinflammation amyloid hypothesis